Glycemic Response to Oral Nutrition Supplements
Not Applicable
Completed
- Conditions
- Diabetes
- Registration Number
- NCT02612675
- Lead Sponsor
- Société des Produits Nestlé (SPN)
- Brief Summary
This will be a randomized, cross-over study of two oral nutrition supplements in individuals with Type 2 Diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
- Age 20-75 yrs
- Type 2 diabetes controlled with diet or diet and oral agent, with the exception of sulfonylureas such as glimepiride (Amaryl), glipizide (Glucotrol/Glucotrol XL) and glyburide (DiaBeta, Micronase, Glynase Prestabs); meglitinides such as reaglinide (Prandin) and nateglinide (Starlix); and alpha-glucosidase inhibitors such as acarbose (Precose) and miglitol (Glyset)
- Hemoglobin A1C less than 9.0%
- Fasting blood glucose less than 180 mg
Exclusion Criteria
- Allergy to milk protein or any other component of the formula
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Area under the blood glucose curve (AUC 0-240) Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Diabetes & Glandular Disease Clinic, PA
🇺🇸San Antonio, Texas, United States
Diabetes & Glandular Disease Clinic, PA🇺🇸San Antonio, Texas, United States